Community/Retail

Bayer HealthCare and Sprint Bioscience AB have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates.

Pharmacists must be aware that edoxaban should not be used in any patient with a creatinine clearance >95 ml/min.

Drones could help local medical services deliver medications to greatly underserved populations.

Get ready to substitute these generics, if you aren't doing so already.

As many as 1 in 10 health care providers prescribe antibiotics for almost every patient they see with a cold or bronchitis, despite the fact that antibiotics are not effective against these viral infections.

Biogen and the Parkinson's Institute and Clinical Center today announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson's disease.

In my limited experience at retail pharmacies, I rarely see patients being counseled.

Naloxone expanded-access provisions that recently took effect in Colorado practically push pharmacists to provide the opioid overdose antidote to anyone requesting it.

Genzyme announced that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a rare disease therapy, indicated for progressive medullary thyroid carcinoma.

There are those outside of family who shape your life, and most of them are teachers.

Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).

Alex Wei, Rutgers University Ernest Mario School of Pharmacy student, discusses why he chose to go to Rutgers.

This episode of the Pharmacy Podcast Show involves Tyrone Squires, founder and managing director of TransparentRx LLC, a boutique pharmacy benefits management firm based in Henderson, Nevada.

Gilead Sciences, Inc. announced the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President.

The Novartis Foundation announces four new members of its Board of trustees.

Teva Pharmaceutical Industries Ltd. today announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V.

Teva Pharmaceutical Industries Ltd. today announced that it has signed a definitive agreement with Allergan plc(NYSE:AGN) to acquire Allergan Generics in a transaction valued at $40.5 billion.

At the front lines of health care, pharmacists may be in a position to encourage obese patients to lose weight.

Pharmacists may have noticed greater emergency contraception (EC) use among teens over the last decade, a new US Centers for Disease Control and Prevention (CDC) study suggests.

Blessy George, PharmD, PhD candidate in toxicology at Rutgers University discusses the most rewarding part of pharmacy school.

Stephen F. Eckel, PharmD, MHA, Pharmacy Times Health-System Edition editor and associate professor at the Eshelman School of Pharmacy at University of North Carolina, discusses the global pharmacy school alliance.

The FDA has expanded the indication for Amgen's carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone to treat patients with relapsed multiple myeloma who have received at least 1 prior therapy.

With biosimilars set to enter the US health care market, pharmacists will soon have new factors to consider when selecting and dispensing products.

The Institute for Safe Medicine Practices (ISMP) recently outlined safe practices for certain error-prone medications.

Paola Acevedo, Rutgers University Ernest Mario School of Pharmacy student, gives advice to students heading to pharmacy school.

Blessy George, PharmD, PhD candidate in toxicology at Rutgers University gives advice to future pharmacy students.

Each of these OTC products will be sitting on your pharmacy's shelves soon, if they aren't already.

A pharmacy employee recently thwarted a theft by pointing a gun at the suspected robber.

This weekly video program highlights the latest in pharmacy news, product news, and more.

The FDA today approved the first cholesterol-lowering PCSK9 inhibitor alirocumab (Praluent).